Integrase inhibitors go head-to-head

Affiliations

¹ Chelsea and Westminster National Health Service Foundation Trust, London SW10 9NH, UK; Imperial College London, London, UK. Electronic address: t.barber@nhs.net.

Comment

Tristan Barber. Lancet HIV. 2017 Apr.

. 2017 Apr;4(4):e142-e143.

doi: 10.1016/S2352-3018(17)30017-6. Epub 2017 Feb 15.

¹ Chelsea and Westminster National Health Service Foundation Trust, London SW10 9NH, UK; Imperial College London, London, UK. Electronic address: t.barber@nhs.net.

No abstract available

Comment on

Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial.
Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Sax PE, et al. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15. Lancet HIV. 2017. PMID: 28219610 Clinical Trial.